XNAS · Healthcare · Medical Devices
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.20 | -0.24 | -20.00% | $19.7M | ❌ Miss | +0.00% | +13.95% | — |
| 2026-03-04 | Q4 2025 | -0.15 | -0.08 | +46.67% | $20.4M | ✅ Beat | -4.81% | -31.61% | -34.94% |
| 2025-11-06 |
| Q3 2025 |
| -0.26 |
| -0.16 |
| +38.46% |
| $19.9M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -0.27 | -0.23 | +14.81% | $19.6M | ✅ Beat | +0.00% | +19.72% | +3.94% |
| 2025-03-05 | Q4 2024 | -0.18 | -0.23 | -27.78% | $19.1M | ❌ Miss | +2.89% | +11.16% | -4.96% |
| 2024-11-07 | Q3 2024 | -0.21 | -0.22 | -4.76% | $20.2M | ❌ Miss | -9.62% | -17.52% | -14.74% |
| 2024-08-01 | Q2 2024 | -0.30 | -0.25 | +16.67% | $21.4M | ✅ Beat | -14.96% | -21.43% | -15.23% |
| 2024-05-02 | Q1 2024 | -0.28 | -0.33 | -17.86% | $19.3M | ❌ Miss | +6.24% | -0.89% | +23.71% |
Showing last 8 quarters.